MA52300A - Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer - Google Patents

Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer

Info

Publication number
MA52300A
MA52300A MA052300A MA52300A MA52300A MA 52300 A MA52300 A MA 52300A MA 052300 A MA052300 A MA 052300A MA 52300 A MA52300 A MA 52300A MA 52300 A MA52300 A MA 52300A
Authority
MA
Morocco
Prior art keywords
neoplasics
platinum
cancer
agents
treatment
Prior art date
Application number
MA052300A
Other languages
English (en)
French (fr)
Inventor
Folgueira Judit Anido
Patricia Anne Giblin
Robin Matthew Hallett
Jeanne Magram
Naimish Pandya
Suarez Joan Seoane
Angus Sinclair
Robert Wasserman
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Inst Catalana Recerca Estudis Avancats
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron, Inst Catalana Recerca Estudis Avancats, Medimmune Ltd filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Publication of MA52300A publication Critical patent/MA52300A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052300A 2018-06-18 2019-06-17 Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer MA52300A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18

Publications (1)

Publication Number Publication Date
MA52300A true MA52300A (fr) 2021-04-21

Family

ID=62837845

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052300A MA52300A (fr) 2018-06-18 2019-06-17 Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer

Country Status (12)

Country Link
US (1) US20210187106A1 (OSRAM)
EP (1) EP3806899A2 (OSRAM)
JP (2) JP7379390B2 (OSRAM)
KR (1) KR20210022065A (OSRAM)
CN (1) CN112955178B (OSRAM)
AU (2) AU2019291307B2 (OSRAM)
CA (1) CA3103369A1 (OSRAM)
EA (1) EA202092964A1 (OSRAM)
IL (1) IL279444A (OSRAM)
MA (1) MA52300A (OSRAM)
SG (1) SG11202012576QA (OSRAM)
WO (1) WO2019243900A2 (OSRAM)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
AU2016248222A1 (en) 2015-04-17 2017-11-09 Eisai, Inc. Methods for treating lung cancer
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SG11202011170YA (en) * 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof

Also Published As

Publication number Publication date
JP2024023212A (ja) 2024-02-21
EP3806899A2 (en) 2021-04-21
US20210187106A1 (en) 2021-06-24
CN112955178B (zh) 2025-03-11
AU2024204564A1 (en) 2024-07-18
CN112955178A (zh) 2021-06-11
AU2019291307B2 (en) 2024-04-04
KR20210022065A (ko) 2021-03-02
AU2019291307A1 (en) 2021-02-04
EA202092964A1 (ru) 2021-03-30
SG11202012576QA (en) 2021-01-28
WO2019243900A2 (en) 2019-12-26
CA3103369A1 (en) 2019-12-26
WO2019243900A3 (en) 2020-03-05
IL279444A (en) 2021-01-31
JP7603772B2 (ja) 2024-12-20
JP2021533084A (ja) 2021-12-02
JP7379390B2 (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
EP3634430A4 (en) MULTIBIOTICS AND METHOD OF USING THEREFORE
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
EP3796920A4 (en) TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER
IL286248A (en) Tyk2 inhibitors and uses thereof
EP3377042A4 (en) MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
EP3749344A4 (en) METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
EP3430057A4 (en) USE OF APE1 / REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATING CANCER
IL283899A (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
EP3490548A4 (en) ADMINISTRATION OF HYPOXY-ACTIVATED PRODRUGS IN COMBINATION WITH IMMUNO MODULATORS FOR TREATING CANCER
PL3634415T3 (pl) Kompozycje okulistyczne zawierające brymonidynę i ketotifen do zastosowania w leczeniu alergii
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
SG11202008897SA (en) C3-binding agents and methods of use thereof
IL289758A (en) Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
EP3813870C0 (en) CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
EP3645120A4 (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
MA52231A (fr) Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer